E2F1 and neoplasm: In contrast, disruption of the Rb pathway and increased activity of the E2F1 promoter in cancer cells still allowed effective replication of Ads inside cells, despite the mutation in the E1A region,[46] thereby leading to a faster replication and shorter infection cycle of Ads in tumor cells than in normal cells (Figures S3 and S4, Supporting Information).